Media headlines about Sage Therapeutics (NASDAQ:SAGE) have been trending somewhat positive on Saturday, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sage Therapeutics earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.0883554916654 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:

Shares of Sage Therapeutics (NASDAQ SAGE) traded up 1.28% during trading on Friday, reaching $84.68. 252,288 shares of the company’s stock were exchanged. The stock’s market cap is $3.17 billion. Sage Therapeutics has a 12-month low of $35.02 and a 12-month high of $90.43. The company has a 50 day moving average of $81.82 and a 200 day moving average of $70.17.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.63) by $0.25. During the same quarter last year, the firm earned ($1.08) EPS. Equities research analysts anticipate that Sage Therapeutics will post ($7.38) EPS for the current year.

A number of analysts recently weighed in on SAGE shares. Leerink Swann reissued an “outperform” rating and issued a $97.00 price objective (up from $90.00) on shares of Sage Therapeutics in a research report on Tuesday, June 20th. ValuEngine raised shares of Sage Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Stifel Nicolaus started coverage on shares of Sage Therapeutics in a research report on Wednesday. They issued a “buy” rating and a $104.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and issued a $82.00 price objective on shares of Sage Therapeutics in a research report on Tuesday, June 13th. Finally, Canaccord Genuity set a $110.00 price objective on shares of Sage Therapeutics and gave the stock a “buy” rating in a research report on Saturday, August 5th. Four investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $89.64.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Insider Buying and Selling by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with's FREE daily email newsletter.